

### About BioSyent

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. These products occupy a niche in the market, provide novel technological or therapeutic advantages, are unique due to the complexity of the manufacturing process, and are backed by strong partners who hold intellectual property rights that are defensible. BioSyent is focused on Canada and certain other international regions.

Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the governmental regulatory approval process. Once approved, BioSyent commercializes the product throughout the territories.

BioSyent's business model is structured to minimize risk and to produce, profitable growth. For the three years ending December 31, 2018, the Company experienced a compound annual revenue growth rate (CAGR) of 12% while delivering a NIAT CAGR of 15% during the same period.

### At a Glance - Financial Information

#### Revenue

2014	\$ 12,211,127
2015	\$ 15,388,196
2016	\$ 17,922,270
2017	\$ 20,762,755
2018	\$ 21,527,028

#### Cash Generation

2014	\$ 2,608,034
2015	\$ 1,726,366
2016	\$ 4,023,810
2017	\$ 5,599,149
2018	\$ 5,086,666

#### Net Income After Tax

2014	\$ 3,154,079
2015	\$ 3,764,889
2016	\$ 4,309,505
2017	\$ 5,206,277
2018	\$ 5,705,386

#### Earnings Per Share (Diluted)

2014	\$ 0.22
2015	\$ 0.26
2016	\$ 0.30
2017	\$ 0.36
2018	\$ 0.39

#### EBITDA

2014	\$ 4,299,963
2015	\$ 5,118,792
2016	\$ 5,900,080
2017	\$ 6,910,977
2018	\$ 7,405,988



For the seventh consecutive year in 2019, BioSyent was named as one of Canada's fastest growing companies in the GROWTH 500 rankings with a 5 year revenue growth rate of 176%.

### At a Glance - Stock Information

Exchange & Trading Symbol	TSXV: RX
Recent Closing Price (01/10/2019)	\$6.22
52 Week High / Low	\$9.98 / \$5.69
Current Shares	13,639,545
Market Cap	\$84,837,970
Warrants	0
Options (21/08/2019)	177,512
Fully Diluted (21/08/2019)	13,817,057

### BioSyent's Products

#### Domestic Market

Marketed Products Approved	8
Approved Products (not Marketed)	1

#### International Market

International Markets Signed	10
Brand Sold In	6

### At a Glance - 5 Years of Growth

	2013 (Base Year)	2018	5 Year Change
Revenue	\$ 7.8M	\$ 21.5M	2.8x
# of Marketed Pharma Products	3	8	2.7x
Net Income Before Tax (NIBT)	\$ 2.5M	\$ 7.5M	3.0x
Cash Generation	\$ 2.1M	\$ 5.1M	2.4x
Cash	\$ 4.4M	\$ 24.4M	5.5x
Debt	\$ 0	\$ 0	-
Fully Diluted Shares*	14,501,195	14,583,139	+0.57%
Diluted EPS	\$ 0.13	\$ 0.39	3.0x

\*Last equity financing - 2002

### Contact Information

#### Investor Relations

905.206.0013 x323  
 Investors@BioSyent.com  
 www.BioSyent.com

#### Address

2476 Argentia Road, Suite 402  
 Mississauga, Ontario  
 L5N 6M1, Canada